
Multiple sclerosis zzso is a complex, incurable zzso Treatment consists of lifelong disease and symptom zzso zzso therapies for zzso zzso include subcutaneous zzso zzso zzso zzso zzso IM zzso zzso SC zzso zzso zzso zzso zzso and zzso zzso all of which are known as zzso agents zzso zzso that can be initiated and continued on a long-term basis can be referred to as platform zzso During periods of disease instability with increased disease activity, zzso or zzso agents can be used in combination with appropriate zzso platform therapy to help control zzso To date, long-term comparative studies of zzso are not zzso However, based on the effects of these agents on disability zzso zzso rates, zzso zzso and zzso zzso observed in phase III zzso clinical trials, zzso products are the zzso of choice for platform therapy for zzso Evidence indicates that zzso may also be beneficial in the early stages of the zzso Research is ongoing to identify other appropriate zzso agents zzso zzso zzso to be used in combination with existing zzso to effectively manage zzso 

